Low-activity (2.0 GBq; 54 mCi) radioiodine post-surgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low-risk patients
Authors:
- M ChianelliMCM Chianelli
- V TodinoVTV Todino
- F M GrazianoFGF M Graziano
- C PanunziCPC Panunzi
- D PaceDPD Pace
- R GuglielmiRGR Guglielmi
- A SignoreA Signore
- E PapiniEPE Papini
- 1 March 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 160 (3) , 431-436
Abstract
Objective: (a) To compare the efficacy of low-activity (2 GBq; 54 mCi) 131I ablation using l-thyroxine withdrawal or rhTSH stimulation, and (b) to assess the influence of thyroid remnants volume on the ablation rate.Design: Patients underwent neck ultrasound, 131I neck scintigraphy and radioiodine uptake. Post-therapy whole body scan (WBS) was acquired after 4–6 days. Ablation was assessed after 6–12 months by WBS, Tg and TgAb following l-thyroxine withdrawal.Methods: Group A: preparation by L-T4 withdrawal (37 days); 21 patients received 131I (2.02±0.22 GBq; 54.6±5.9 mCi) and on the day of treatment, TSH, Tg, TgAb were measured; Group B: stimulation by rhTSH; 21 patients received 131I (1.97±0.18 GBq; 53.2±4.9 mCi) 24 h after the second injection of rhTSH (0.9 mg) and TSH, Tg and TgAb were measured after 2 days.Results: At follow-up, 90.0% of patients from group A and 85.0% of patients from group B had Tg levels 131I treatment, small thyroid remnants (131I (2 GBq; 54 mCi) is safe and effective and avoids hypothyroidism. The presence of thyroid remnants smaller than 1 ml at US evaluation had no effect on the ablation rate.Keywords
This publication has 12 references indexed in Scilit:
- A Comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-Iodine Administered Doses for Recombinant Thyrotropin-Stimulated Postoperative Thyroid Remnant Ablation in Differentiated Thyroid CancerThe Journal of Clinical Endocrinology & Metabolism, 2007
- European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epitheliumEuropean Journal of Endocrinology, 2006
- Radioiodine Ablation of Thyroid Remnants after Preparation with Recombinant Human Thyrotropin in Differentiated Thyroid Carcinoma: Results of an International, Randomized, Controlled StudyThe Journal of Clinical Endocrinology & Metabolism, 2006
- Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines TaskforceThyroid®, 2006
- Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus reportEuropean Journal of Endocrinology, 2005
- Second primary malignancies in thyroid cancer patientsBritish Journal of Cancer, 2003
- Radioiodine Treatment with 30 mCi after Recombinant Human Thyrotropin Stimulation in Thyroid Cancer: Effectiveness for Postsurgical Remnants Ablation and Possible Role of Iodine Content inl-Thyroxine in the Outcome of AblationThe Journal of Clinical Endocrinology & Metabolism, 2003
- Ablation of Thyroid Residues with 30 mCi 131I: A Comparison in Thyroid Cancer Patients Prepared with Recombinant Human TSH or Thyroid Hormone WithdrawalThe Journal of Clinical Endocrinology & Metabolism, 2002
- Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancerThe American Journal of Medicine, 1994
- Natural History, Treatment, and Course of Papillary Thyroid Carcinoma*The Journal of Clinical Endocrinology & Metabolism, 1990